Literature DB >> 31695136

Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial.

R Rasheedy1, G El Bishry2, R Tarek2.   

Abstract

OBJECTIVES: To compare the effect of sildenafil citrate (SC) and low molecular weight heparin (LMWH) on neonatal birth weight (BW) and the fetoplacental blood flow in pregnancies with FGR. STUDY
DESIGN: A parallel groups, randomized clinical trial was conducted at a university hospital, between June 2017 and September 2018, involving 100 pregnant women with placental mediated FGR between 28 and 35 weeks of gestation who were randomly assigned to receive either SC or LMWH started at FGR diagnosis till delivery.
RESULTS: The neonatal BW in LMWH group was higher than SC group (p < 0.000) with a longer time from randomization till delivery, LMWH group had significant improvement in Ut A PI, UA PI, and MCA PI compared with SC treated group with p values 0.005, <0.000001, and 0.014, respectively.
CONCLUSION: The neonatal BW, time from randomization to delivery, and fetoplacental blood flow indices were significantly better with LMWH use compared with SC.

Entities:  

Year:  2019        PMID: 31695136     DOI: 10.1038/s41372-019-0544-1

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  25 in total

1.  Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices.

Authors:  A Trapani; L F Gonçalves; T F Trapani; M J Franco; R N Galluzzo; M M S Pires
Journal:  Ultrasound Obstet Gynecol       Date:  2016-07       Impact factor: 7.299

2.  Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.

Authors:  J P Newnham; M Godfrey; B J Walters; J Phillips; S F Evans
Journal:  Aust N Z J Obstet Gynaecol       Date:  1995-11       Impact factor: 2.100

3.  Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression.

Authors:  Silvia D'Ippolito; Fiorella Di Nicuolo; Riccardo Marana; Roberta Castellani; John Stinson; Chiara Tersigni; Giovanni Scambia; Nicoletta Di Simone
Journal:  Fertil Steril       Date:  2012-07-19       Impact factor: 7.329

Review 4.  Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol.

Authors:  Francesc Figueras; Eduard Gratacós
Journal:  Fetal Diagn Ther       Date:  2014-01-23       Impact factor: 2.587

5.  Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor.

Authors:  Y Yinon; E Ben Meir; L Margolis; S Lipitz; E Schiff; S Mazaki-Tovi; M J Simchen
Journal:  Placenta       Date:  2014-12-20       Impact factor: 3.481

Review 6.  Aberrant maternal inflammation as a cause of pregnancy complications: A potential therapeutic target?

Authors:  T Cotechini; C H Graham
Journal:  Placenta       Date:  2015-06-04       Impact factor: 3.481

7.  Heparin for patients with growth restricted fetus: a prospective randomized controlled trial.

Authors:  Yan-Hong Yu; Li-Yong Shen; Hua Zou; Zhi-Jian Wang; Shi-Peng Gong
Journal:  J Matern Fetal Neonatal Med       Date:  2010-09

Review 8.  Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.

Authors:  Nazli Hossain; Michael J Paidas
Journal:  Semin Perinatol       Date:  2007-08       Impact factor: 3.300

Review 9.  Intrauterine growth restriction, human placental development and trophoblast cell death.

Authors:  Christina M Scifres; D Michael Nelson
Journal:  J Physiol       Date:  2009-05-18       Impact factor: 5.182

10.  Sildenafil citrate in fetal growth restriction.

Authors:  Subrat Panda; Ananya Das; Hossain Md Nowroz
Journal:  J Reprod Infertil       Date:  2014-07
View more
  1 in total

1.  Thromboangiitis obliterans in pregnancy - Case report and literature review.

Authors:  Hannah E Farquhar; Annabelle Lamprecht
Journal:  Obstet Med       Date:  2021-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.